Pain and QoL Data Presented for Gore’s Viabahn Fortegra Venous Stent

April 22, 2026—Gore & Associates announced new 12-month findings from the global GORE VIABAHN FORTEGRA Venous Stent IVC trial, which evaluated treatment of patients with symptomatic deep venous iliocaval obstruction.

Sonorous BosCath Neurovascular Catheter Cleared by FDA

April 22, 2026—Sonorous Neurovascular, a developer of solutions for cerebral venous diseases and neurovascular interventions, announced that it has received FDA 510(k) clearance for its BosCath, allowing the company to commercialize the next-generation neurovascular catheter in the United States.

Boston Scientific TheraSphere Y90 Glass Microspheres Evaluated in PROACTIF Registry

April 22, 2026—Boston Scientific announced an analysis of 989 patients with hepatocellular carcinoma (HCC) from the PROACTIF prospective real-world registry.

Efemoral Vascular Scaffold System Evaluated in Long-Term Results From FIH Trial

April 22, 2026—Efemoral Medical announced long-term results of the first 40 patients treated in the EFEMORAL I first-in-human (FIH) clinical trial of the Efemoral vascular scaffold system (EVSS).

Gore Introduces Excluder TAMBE Device in Europe

April 22, 2026—Gore & Associates announced that its Excluder thoracoabdominal branch endoprosthesis (TAMBE) received CE Mark approval earlier this year and is being introduced in hospitals across Europe.

Data Presented From Pilot Trial of InVera Infusion Device for Chronic Venous Disease 

April 21, 2026—InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of chronic venous disease (CVD).

Study Highlights Insurance-Based Disparities in TEVAR for TBAD

April 21, 2026—In this retrospective analysis, Zil-E-Ali et al found that patients with government-funded insurance who underwent urgent or emergent thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD) presented with more advanced disease and experienced significantly higher short- and long-term mortality than commercially insured patients.

Elucid Introduces Lesion Inspection Tool for Plaque-IQ Software Suite

April 20, 2026—Elucid announced the commercial availability of a new lesion inspection tool for coronary and carotid plaque analysis in its Plaque-IQ software suite.